VEXAS syndrome

A roundup of the week's most newsworthy health industry press releases from PR Newswire, including Kroger's new clinical trial site network and a new wellbeing center for children. NEW YORK, Jan. 27, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Healthcare Press Release Roundup, Jan. 23-27, 2023. Photo provided by Xylyx Bio, Inc. More Americans Know Their Horoscope Sign Than Their Blood Type, Survey Reveals Aimed to empower Americans to take ownership of their health in the new year, the survey highlights how the U.S. adult population prioritizes their health, where they go for medical advice, and how proactive they are with staying on top of their overall well-being. Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for transplant, according to a recent study published in The Journal of Heart and Lung Transplantation. Cincinnati Children's Opens First-of-its-Kind Heart and Mind Wellbeing Center in United States The Heart and Mind Wellbeing Center was created to provide comprehensive psychological support and mental health care tailored for families affected by Congenital Heart Disease (CHD). It offers research-proven treatments focused on enhancing both physical and mental health. New Online Tool Provides Health Snapshot of All 435 U.S. Congressional Districts The Congressional District Health Dashboard can inform policymaker action to eliminate wide disparities in premature death, mental health, childhood poverty, broadband access, and more. Study Offers First Glimpse of How Many Suffer From Previously Unknown Illness About 13,200 men and another 2,300 women in the United States over age 50 are estimated to have VEXAS syndrome, according to a new study. Start-up Pitch Finalists Announced for AMWA Healthcare Innovation Challenge "Women physicians and other women healthcare leaders play critical roles in our healthcare system and we represent and have a unique understanding of the needs of women patients," said AMWA President, Theresa Rohr-Kirchgraber, MD. "These are some of the many reasons it's a strategic miss that women-led startups receive less than 3% of venture capital funding." HLTH Foundation Launches 'Techquity for Health' Coalition to Help Integrate Health Equity Standards into Healthcare Technology & Data Practices The Coalition defines techquity as the strategic design, development, and deployment of technology to advance health equity, and encompasses the notion that technology can inhibit advancements in health equity if not implemented intentionally and inclusively. Kroger Health Establishes Clinical Trial Site Network to Increase Reach and Access to Research Studies "With our team of more than 24,000 healthcare professionals, under the umbrella of America's grocer, we are positioned at the nexus of food and healthcare, which provides us with the unique opportunity to increase accessibility to clinical trial opportunities," said Colleen Lindholz, Kroger Health president. Centivo's 2022 Healthcare Spend Analysis Reveals 21 to 33 Percent Cost Savings for Employers Employees using Centivo also visited primary care physicians more and experienced fewer emergency and inpatient visits than industry benchmarks. Crown Aesthetics Introduces BIOJUVE™, a Revolutionary First of Its Kind, Living Skin Biome Care, Clinically Proven to Deliver Results, 24/7 The microbial powerhouses within the patented Xycrobe™ technology naturally produce and deliver around the clock Bioessentials™ such as proteins, polypeptides, and antioxidants to optimize skin health and vitality. CVS Health Launches Community Equity Alliance to Improve Health Outcomes in Underserved Communities The CVS Health Community Equity Alliance is being established to expand the community health worker workforce, enhance connections between health care institutions and communities and address disparities in heart health and mental health outcomes. Responder Health and Youturn Health Partner to Provide Mental Health Support for First Responders "It is absolutely critical to get the men and women who keep us safe the support they need to treat chronic stress and trauma," said Sean Riley, Co-Executive Director of Responder Health. "We're working to break the code of silence that causes officers of the law to needlessly suffer." Read more of the latest health-related releases from PR Newswire and stay caught up on the top press releases by following @PRNhealth on Twitter. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers and freelancers have access to the following free features: Customization: Create a customized newsfeed that will deliver relevant news right to your inbox. Customize the newsfeed by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include with your next story. Subject Matter Experts: Access ProfNet, a database of industry experts to connect with as sources or for quotes in your articles. Related Resources: Read and subscribe to our journalist- and blogger-focused blog, Beyond Bylines, for media news roundups, writing tips, upcoming events, and more. About PR Newswire and PR Newswire for Journalists For more than 65 years, PR Newswire has been the industry leader with the largest, most comprehensive distribution network of print, radio, magazine, television stations, financial portals and trade publications. PR Newswire has an unparalleled global reach of more than 200,000 publications and 10,000 websites and is available in more than 170 countries and 40 languages. PR Newswire for Journalists (PRNJ) is an exclusive community that includes over 20,000 journalists, bloggers and influencers who are logging into their PRNJ accounts specifically looking for story ideas. PR Newswire thoroughly researches and vets this community to verify their identity as a member of the press, blogger or influencer. PRNJ users cover more than 200 beats and verticals. For questions, contact the team at [email protected]. SOURCE PR Newswire

Courtesy Getty Images A study published Tuesday in JAMA revealed a little-known syndrome with a high mortality rate has a higher prevalence than previously thought. VEXAS was first identified in 2020, and patients exhibit unexplained fevers, anemia and inflammation. The lead investigator for the study, David Beck, M.D., Ph.D., also led the team that initially identified the UBA1 gene mutation shared amongst VEXAS patients. His team utilized that knowledge to screen the blood DNA records of 163,096 consenting patients in the Pennsylvania healthcare system. The UBA1 mutation was found in nine males and two females. While these figures maintain the disease's rare status, the previous 2020 findings identified 25 men and no women in the U.S. with the condition. This new study, led by researchers at NYU Grossman School of Medicine, suggests the rare condition is more vexing than originally thought – 1 in 4,269 men and 1 in 26,238 women, over 50. Mayo Clinic rheumatologist Matthew Koster, M.D., called the findings “remarkable.” “Is VEXAS really more common than we think, with patients hiding in plain sight? And the answer is yes.” Proving the greater prevalence in men is of particular importance as that population carries the higher mortality rate. Up to half of people diagnosed with VEXAS, mostly men, die within five years. The study's participants lacked diversity – 94% were white and 61% were female, all based in Pennsylvania. The team plans to analyze more racially diverse groups and look for additional genetic causes. The team said they believe their findings will raise awareness of the disease to increase accurate diagnoses and open avenues for new therapies. Development of a simple blood test for the UBA1 mutation is also on the to-do list, to make for an easier, earlier diagnosis. Current treatments for the disease include high-dose steroids, JANUS kinase inhibitors and bone marrow transplants to control symptoms.

NEW YORK, Jan. 24, 2023 /PRNewswire/ -- About 13,200 men and another 2,300 women in the United States over age 50 are estimated to have VEXAS syndrome, according to a new study. Long considered a mystery illness until its genetic basis was identified in 2020, the latest findings, led by researchers at NYU Grossman School of Medicine, offer the first indication of how common the illness is domestically. Although a rare disorder, the syndrome carries a high mortality rate, with up to half of people, mostly men, dying within five years of diagnosis. The syndrome most often involves unexplained fevers and low blood oxygen levels in people diagnosed with other diseases, such as rheumatoid arthritis, lupus, and blood cancer. Some of the symptoms have been linked to an overactive immune system, which can cause inflammation and classifies the syndrome as an autoimmune condition. Researchers say they hope their findings will raise awareness of the disorder among physicians, particularly because high-dose steroids, JANUS kinase inhibitors, and bone marrow transplantation have proven effective in controlling some symptoms. "Now that we know VEXAS syndrome is more common than many other types of rheumatologic conditions, physicians need to add this condition to their list of potential diagnoses when confronted by patients with persistent and unexplained inflammation and low blood cell counts, or anemia," says geneticist and study lead investigator David Beck, MD, PhD. Beck, an assistant professor in the Department of Medicine and the Department of Biochemistry and Molecular Pharmacology at NYU Langone Health, also led the federal research team that initially identified the shared UBA1 mutation among VEXAS patients. In the new study, publishing in the Journal of the American Medical Association (JAMA) online Jan. 24, researchers analyzed the electronic health records of 163,096 mostly white men and women in Pennsylvania who agreed to have their blood DNA screened for signs of genetic disease. Twelve were found to have the UBA1 mutation, with all experiencing VEXAS symptoms. Statistically, this corresponded to one in 4,269 American men over age 50 and one in 26,238 women over age 50 having or are likely to develop the syndrome. This, researchers say, is a higher prevalence figure than many other inflammatory conditions, including vasculitis and myeloid dysplasia syndrome. "Our study offers the first glimpse of just how common VEXAS syndrome is in the United States, particularly among men, who also happen to be the most to die from it," says Beck, who is leading several clinical research efforts into VEXAS syndrome at NYU Langone's Center for Human Genetics and Genomics. Previous research, led by Beck, traced the origins of the syndrome to a mutation, or change in the letter code that makes up DNA, in the gene UBA1 (short for ubiquitin-like modifier activating enzyme 1.) The enzyme usually assists in protein breakdown. VEXAS stands for many of its biological characteristics: vacuoles in blood cells, the E1 enzyme, X-linked, autoinflammatory, and somatic. For the study, researchers analyzed the electronic medical records of adult patients who volunteered to participate in the Geisinger MyCode Community Health Initiative. The program has been collecting data for more than 25 years from patients in Geisinger's 10-plus hospitals in Central and Northeastern Pennsylvania. Almost all study participants who agreed to have their blood DNA tested were white; half were over the age of 60. Beck says the team next plans to analyze patient records in more racially diverse groups, especially among those with higher rates of rheumatologic and blood disease, to gain a more precise picture of who is most at risk of VEXAS syndrome. They also plan to look for additional genetic causes, test new therapies for the syndrome, and develop a simple blood test for UBA1 to make it easier to diagnose. Funding for the study was provided by National Institute of Health grants R00AR078205 and T32GM136542. Besides Beck, other NYU Langone researchers involved in this study are Samuel Magaziner, MPhil; and Ann Cantor, MS. Other study co-investigators are Dale Bodian, PhD, at Geisinger Research in North Bethesda, Md.; Vandan Shah, MD; Uyenlinh Mirshahi, PhD; Natasha Strande PhD; Jeremy Haley, MS; Adam Cook, MS; Wesley Hill; Yi Ding, MD, PhD; and David Carey, PhD, at Geisinger Health in Danville, Pa.; Jung Kim, PhD, and Douglas Stewart, at the National Cancer Institute in Rockville, Md.; Alan Schwartz, MD, PhD, at the University of Washington in St. Louis, Mo.; Peter Grayson, MD, and Marcela Ferrada, MD, at the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda; and Daniel Kastner, MD, at the National Human Genome Research Institute, also in Bethesda. Media Inquiries David March Phone: 212-404-3528 [email protected] SOURCE NYU Langone Health